1. Scrip
  2. >>Business

More Is Better? UK Crowdfunding Platform Selects First Firms

 
• By John Davis

Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.

Crowdfunding
Adding to investment funds • Source: Shutterstock

The ability of web-based "crowdfunding" platforms to more easily attract and aggregate investment funding for start-up companies in the UK biotech sector is to be put to the test with Capital Cell, a three-year-old European crowdfunding firm that has just released details of its first four UK investment possibilities.

Capital Cell appears to be the first life sciences-dedicated crowdfunding platform to be set up in the UK, and the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.